We previously demonstrated that rosiglitazone inhibited the activation of the PI3-K/Akt/mTOR signaling pathway in NSCLC cells [11] and, therefore, set out to explore the effects of rosiglitazone on modulators of this pathway. Here, AKT1 is linked to non-small cell lung carcinoma.